AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 83 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $223,304 | -94.7% | 21,680 | -91.6% | 0.00% | -100.0% |
| Q2 2023 | $4,252,664 | +1692.6% | 258,050 | +896.4% | 0.00% | – |
| Q1 2023 | $237,235 | -55.8% | 25,899 | -65.4% | 0.00% | – |
| Q4 2022 | $536,277 | +562.1% | 74,899 | +125.5% | 0.00% | – |
| Q2 2022 | $81,000 | -72.3% | 33,220 | -22.4% | 0.00% | – |
| Q1 2022 | $292,000 | -78.3% | 42,804 | -74.3% | 0.00% | – |
| Q4 2021 | $1,348,000 | +164.3% | 166,869 | +220.9% | 0.00% | – |
| Q3 2021 | $510,000 | +335.9% | 52,000 | +198.9% | 0.00% | – |
| Q2 2021 | $117,000 | -89.3% | 17,397 | -85.6% | 0.00% | – |
| Q1 2021 | $1,094,000 | +835.0% | 121,005 | +589.7% | 0.00% | – |
| Q4 2020 | $117,000 | +23.2% | 17,545 | +50.0% | 0.00% | – |
| Q2 2020 | $95,000 | +66.7% | 11,700 | -15.3% | 0.00% | – |
| Q3 2019 | $57,000 | – | 13,819 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |